Abstract Title:

MagnetisMM-30: Aphase1b,open-label study of elranatamab in combination with iberdomide in patients with relapsed or refractory multiple myeloma (RRMM)

Summary:

Dr. Alexander Lesokhin outlines a phase 1b clinical study called MagnetisMM-30, which aims to evaluate the safety, efficacy, and pharmacokinetics of the combination of elranatamab (ELRA) and iberdomide (IBER) in patients with relapsed or refractory multiple myeloma (RRMM). ELRA is a humanized B-cell maturation antigen (BCMA)–CD3 bispecific antibody, while IBER is a novel CELMoD[TM] agent. The study consists of two parts: Part 1 for dose-escalation and Part 2 for dose optimization. Patients will receive subcutaneous ELRA weekly and IBER daily for 21 days of each 28-day cycle. After 6 months of treatment, patients with a partial response or better for at least 2 months may be eligible for reduced dosing frequency of ELRA. The study aims to enroll approximately 27 patients in Part 1 and 60 patients in Part 2. The primary endpoints of the study include dose-limiting toxicities, adverse events, overall response rate, complete response rate, time-to-event outcomes, pharmacokinetics, minimal residual disease negativity rate, and immunogenicity.

Key Points:

• The study is evaluating the combination of elranatamab (ELRA) and iberdomide (IBER) in patients with relapsed or refractory multiple myeloma (RRMM). ​
• ELRA is a humanized B-cell maturation antigen (BCMA)–CD3 bispecific antibody, while IBER is a novel CELMoD[TM] agent. ​
• The study has two parts: Part 1 for dose-escalation and Part 2 for dose optimization. ​
• Patients will receive subcutaneous ELRA weekly with IBER given daily for 21 days of each 28-day cycle. ​
• After 6 months of treatment, patients with a partial response or better for at least 2 months are eligible for reduced dosing frequency of ELRA. ​
• The study will enroll approximately 27 patients in Part 1 and 60 patients in Part 2. ​
• The primary endpoints of the study include dose-limiting toxicities, adverse events (AEs), lab abnormalities, overall response rate (ORR), complete response rate (CRR), time-to-event outcomes, pharmacokinetics (PK), minimal residual disease (MRD) negativity rate, and immunogenicity. ​

Authors:

Alexander M. Lesokhin, Muhammed Saleem Raza, Jorge Acosta, Patrick Muller, AshleighO’Connell, Anne Yver, Carolyn Lou, Gregory Finn

ASCO Poster TPS7577